CN105263924B - Cxcr7受体调节剂 - Google Patents

Cxcr7受体调节剂 Download PDF

Info

Publication number
CN105263924B
CN105263924B CN201480030766.2A CN201480030766A CN105263924B CN 105263924 B CN105263924 B CN 105263924B CN 201480030766 A CN201480030766 A CN 201480030766A CN 105263924 B CN105263924 B CN 105263924B
Authority
CN
China
Prior art keywords
ethyl
tetrahydro
isoquinolin
acetamide
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480030766.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263924A (zh
Inventor
H·弗雷茨
P·盖里
T·基梅尔林
F·勒昂布尔
J·波迪尔
H·塞德特
A·瓦尔德内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN105263924A publication Critical patent/CN105263924A/zh
Application granted granted Critical
Publication of CN105263924B publication Critical patent/CN105263924B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
CN201480030766.2A 2013-05-30 2014-05-28 Cxcr7受体调节剂 Expired - Fee Related CN105263924B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
IBPCT/IB2013/054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
CN105263924A CN105263924A (zh) 2016-01-20
CN105263924B true CN105263924B (zh) 2018-10-19

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480030766.2A Expired - Fee Related CN105263924B (zh) 2013-05-30 2014-05-28 Cxcr7受体调节剂

Country Status (30)

Country Link
US (1) US9920010B2 (cg-RX-API-DMAC10.html)
EP (1) EP3004082B1 (cg-RX-API-DMAC10.html)
JP (1) JP6393749B2 (cg-RX-API-DMAC10.html)
KR (1) KR102302580B1 (cg-RX-API-DMAC10.html)
CN (1) CN105263924B (cg-RX-API-DMAC10.html)
AR (1) AR096490A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014272718B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015030095B1 (cg-RX-API-DMAC10.html)
CA (1) CA2912133C (cg-RX-API-DMAC10.html)
CL (1) CL2015003470A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119537T1 (cg-RX-API-DMAC10.html)
DK (1) DK3004082T3 (cg-RX-API-DMAC10.html)
EA (1) EA028604B1 (cg-RX-API-DMAC10.html)
ES (1) ES2645470T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171597T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036649T2 (cg-RX-API-DMAC10.html)
IL (1) IL242782B (cg-RX-API-DMAC10.html)
LT (1) LT3004082T (cg-RX-API-DMAC10.html)
MA (1) MA38679B1 (cg-RX-API-DMAC10.html)
MX (1) MX364104B (cg-RX-API-DMAC10.html)
MY (1) MY173564A (cg-RX-API-DMAC10.html)
NO (1) NO3004082T3 (cg-RX-API-DMAC10.html)
PH (1) PH12015502632B1 (cg-RX-API-DMAC10.html)
PL (1) PL3004082T3 (cg-RX-API-DMAC10.html)
PT (1) PT3004082T (cg-RX-API-DMAC10.html)
SG (1) SG11201509057UA (cg-RX-API-DMAC10.html)
SI (1) SI3004082T1 (cg-RX-API-DMAC10.html)
TW (1) TWI640510B (cg-RX-API-DMAC10.html)
UA (1) UA118562C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014191929A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
EP3490986B1 (en) * 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747929A (zh) * 2002-12-20 2006-03-15 坎莫森特里克斯公司 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂
WO2007059108A2 (en) * 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
RU2214405C2 (ru) 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747929A (zh) * 2002-12-20 2006-03-15 坎莫森特里克斯公司 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂
WO2007059108A2 (en) * 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use

Also Published As

Publication number Publication date
PH12015502632A1 (en) 2016-03-07
MY173564A (en) 2020-02-04
LT3004082T (lt) 2017-10-25
EA028604B1 (ru) 2017-12-29
MA38679B1 (fr) 2019-12-31
PT3004082T (pt) 2017-11-13
HUE036649T2 (hu) 2018-07-30
SG11201509057UA (en) 2015-12-30
US9920010B2 (en) 2018-03-20
KR20160013197A (ko) 2016-02-03
AU2014272718B2 (en) 2018-06-28
BR112015030095B1 (pt) 2023-02-28
JP6393749B2 (ja) 2018-09-19
AU2014272718A1 (en) 2016-01-21
DK3004082T3 (en) 2017-10-02
WO2014191929A1 (en) 2014-12-04
EP3004082A1 (en) 2016-04-13
ES2645470T3 (es) 2017-12-05
EA201501163A1 (ru) 2016-06-30
CY1119537T1 (el) 2018-03-07
IL242782A0 (en) 2016-02-01
PL3004082T3 (pl) 2018-01-31
CA2912133C (en) 2021-06-22
US20160107997A1 (en) 2016-04-21
NZ715530A (en) 2020-12-18
HK1223353A1 (en) 2017-07-28
NO3004082T3 (cg-RX-API-DMAC10.html) 2017-12-30
CL2015003470A1 (es) 2016-06-17
TW201529557A (zh) 2015-08-01
EP3004082B1 (en) 2017-08-02
UA118562C2 (uk) 2019-02-11
MA38679A1 (fr) 2018-07-31
AR096490A1 (es) 2016-01-13
MX2015016429A (es) 2016-03-01
BR112015030095A2 (pt) 2022-07-12
IL242782B (en) 2019-06-30
MX364104B (es) 2019-04-12
KR102302580B1 (ko) 2021-09-15
HRP20171597T1 (hr) 2017-12-01
SI3004082T1 (sl) 2017-11-30
CN105263924A (zh) 2016-01-20
JP2016520120A (ja) 2016-07-11
PH12015502632B1 (en) 2016-03-07
TWI640510B (zh) 2018-11-11
CA2912133A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
TWI640510B (zh) Cxcr7受體調節劑
CN103492370B (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶,其组合物,和用其治疗的方法
CN101141956B (zh) Crth2拮抗剂化合物及其制备方法和制药用途
TW200403210A (en) Benzamide derivatives
KR20050058367A (ko) 피리미딘 유도체 및 그의 cb2 조절제로서의 용도
TW201427953A (zh) 可作爲激酶調節劑之經雜芳基取代的吡啶化合物
KR102791742B1 (ko) (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의 합성을 위한 공정
CN107001279A (zh) Cxcr7受体调节剂
CN110461838A (zh) 噁二唑瞬时受体电位通道抑制剂
JP2007517868A (ja) 治療薬i
JP2019521163A (ja) 二環式プロリン化合物
CN110049985B (zh) 作为RORγ调节剂的杂环砜类
WO2021129629A1 (zh) Zeste增强子同源物2抑制剂及其用途
CN110278711A (zh) 作为RORγ调节剂的三环砜
JPWO2017183723A1 (ja) Kcnq2〜5チャネル活性化剤
JP2004529089A (ja) うつ病および/又は不安症を治療するためのgal3受容体アンタゴニストの使用、およびこのような方法において有用な化合物
CN111566091A (zh) 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基衍生物
JP2005510475A (ja) テトラヒドロイソキノリン、それらの製造方法、および麻酔薬としてのそれらの使用
JP2005510475A6 (ja) テトラヒドロイソキノリン、それらの製造方法、および麻酔薬としてのそれらの使用
HK1223353B (en) Cxcr7 receptor modulators
HK40047161B (en) Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
NZ715530B2 (en) Cxcr7 receptor modulators
JPWO2015108136A1 (ja) α−置換グリシンアミド誘導体
AU2007211954A1 (en) Pyrimidine derivatives and their use as CB2 modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170707

Address after: Swiss Bonneville

Applicant after: IDORSIA PHARMACEUTICALS LTD.

Address before: Swiss Bonneville

Applicant before: Actelion Pharmaceuticals Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181019

CF01 Termination of patent right due to non-payment of annual fee